Current or past participation in a study of an investigational agent or using an investigational device within four weeks of registration for protocol therapy
Use of an investigational agent or an investigational device within 21 days before administration of first dose of study drug(s).
Prior participation in an investigational study (drug, procedure or device) within 21 days of study day 1.
Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s).
Participation in a clinical trial in which the patient received an investigational drug or device must be discontinued at enrollment.
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks prior to study registration
Current or planned participation in a study of an investigational agent or using an investigational device
Are currently enrolled in, or have discontinued within 30 days of screening, from a clinical trial involving an investigational product or non-approved use of a drug or device.
Participation in a study of an investigational agent or device within 4 weeks of Day
Treatment within 30 days prior to randomization with another investigational device or drug study (ies).
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 2 weeks of trial entry (signing of the informed consent form)
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Current or planned participation in a study of another investigational agent or using an investigational device.
Planned participation in another study of an investigational agent or investigational device or planned use of any other agent or therapeutic device intended for therapy of glioma
Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half lives before enrollment or is currently enrolled in the treatment stage of an investigational study
Participation in a clinical trial in which the patient received an investigational drug or device or the off-label use of a drug or device within 3 months of enrollment
Current or planned participation in a study of an investigational agent or using an investigational device
Current enrollment in an investigational drug or device study or participation in such a study within 30 days of cycle 1 day 1.
Currently receiving treatment in another investigational device or drug study.
Currently receiving treatment with another investigational device or drug study, or < 28 days since ending treatment with another investigational device or drug study(s); other investigational procedures while participating in this study are excluded
Current or planned participation in a study of an investigational agent or using an investigational device
Currently receiving treatment in another investigational device or drug study, or less than 30 days between ending treatment on another investigational device or drug study(ies) and start of IP treatment. Other investigational procedures while participating in this study are excluded.
Investigational device within 4 weeks of the first dose of treatment
PHASE I AND PHASE II DOSE EXPANSION IN RECURRENT GBM UNDERGOING RESECTION: Is currently participating in a study of an investigational agent or using an investigational device for therapeutic purposes; concurrent use of Optune device is not allowed
Currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x half-life for investigational drugs where the half-life is known) preceding informed consent
Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)
Currently receiving any investigational drug or device in another clinical trial or within 30 days preceding informed consent.
Use of any investigational product (IP) or investigational medical device within 28 days before day 1 of study drug
Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited
Participation in an investigational drug or device study or treatment with any antineoplastic agent within 14 days of the first day of dosing on this study
Participation in an investigational drug or device study within 14 days of the first day of dosing on this study
Patient is simultaneously participating in another investigational drug or device study
Enrollment in any other investigational treatment study or use of an investigational agent, or has not yet completed at least 3 half-lives since ending another investigational device or drug trial
Patient is currently participating in a study with an investigational compound or device
Subjects who participated in an investigational drug or device study within 28 days prior to study entry
Received an investigational drug, was vaccinated with live attenuated vaccines, or used an invasive investigational medical device within 4 weeks before the planned first dose of study drug, or is currently being treated in an investigational study
Any other investigational agent or used an investigational device within 21 days prior to day 1 of protocol therapy
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 28 days prior to registration
Treatment with another investigational drug (with the exception of anticancer immune therapy) or device, or approved therapy for investigational use, within 5 times the half-life of the drug or within 3 weeks prior to study day 1 if the half life is not known.
Subject participating in any other study involving an investigational (unapproved) drug or device within the past 60 days.
Participated in any other study in which receipt of an investigational new drug or investigational device occurred within 28 days of first dose of study drug
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study
Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.
Concurrent use of another investigational drug or device therapy (ie, outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form).
Have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.
Are currently enrolled in another clinical study or used any investigational drug or device within 30 days (or 5 x the half-life of the investigational drug/device, whichever is longer) preceding informed consent
Prior or concurrent exposure to any of the following: approved or investigational treatments for SMM or/and multiple myeloma, daratumumab or other anti CD-38 therapies, treatment with corticosteroids with a dose greater than (>) 10 milligram (mg) prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates, denosumab) or are only allowed if given in a stable dose and for a nonmalignant condition, or received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1
Participation in any other investigational drug trial or exposure to other investigational agent, device or procedure within 30 days
Participant has received an investigational drug or used an invasive investigational medical device within 30 days prior to Study Entry or is currently enrolled in an investigational study
Concurrent use of another investigational drug or device (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Used an investigational device within 4 weeks of the first dose of treatment
The participant is currently enrolled in a clinical trial involving an investigational product or non-approved use of a drug or device.
Current or planned participation in a study of an investigational agent or using an investigational device
Patient has received an investigational agent or used an investigational device within 28 days of the first dose of study drug
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 21 days of trial entry (signing of the informed consent form)
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of cycle 1, day 1
Receipt of treatment with another investigational device or drug
Received ibrutinib or following therapies considered investigational for treatment of cGVHD including imatinib, bortezomib, ruxolitnib, or entospletinib, within 4 wks prior to starting AMG 592 or is currently receiving treatment in another investigational drug or device study.
Current enrollment in an investigational drug or device study or participation in such a study within 30 days of enrollment
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Patients who have not yet completed at least 21 days (30 days for prior monoclonal antibody therapy) since ending other investigational device or drug trials, or who are currently receiving other investigational treatments
Currently participating or enrolled in another investigational treatment, device or drug study through follow up
Subjects who participated in any other investigational drug trial or had exposure to any other investigational agent, device or procedure <4 weeks prior to Screening and throughout the entire trial, with the exception of investigational drugs administered prophylactically for CMV post allogeneic HCT.
Participation in a clinical trial of an investigational device or drug within 4 weeks of study entry.
Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s)
Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Concurrent use of another investigational drug or device during, or within 3 weeks of starting study treatment
Concurrent use of another investigational drug or device during, or within 3 weeks of starting study treatment
Participation in any other investigational trial in which receipt of investigational drug or device occurred within 30 days prior to screening for this study
Current enrollment in another interventional clinical study or used any investigational drug or device within the past 28 days preceding informed consent.
Participant who were treated with other investigational drug or medical device within 4 weeks prior to the planned first day of study drug dosing.
Prior participation in an investigational study (procedure or device) within 21 days of study day 1
Any other investigational drug/medical device within 3 weeks prior to the first dose
Participation in concurrent study of an investigational agent or device.
Participating in another investigational drug or device trial that has not completed the follow-up period
Participant has been exposed to an investigational product (IP) or investigational device in another clinical study within 4 weeks prior to IP administration, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
Treatment with another investigational drug or device within 28 days prior to Day 1
Currently enrolled in another investigational device or drug study
Use of investigational drug within 4 weeks of Day 1 Week 1 or current enrollment in an investigational drug or device study
Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s) or subject is receiving other investigational agents.
Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or subject is receiving other investigational agent(s)
Patients who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half -lives before registration or is currently enrolled in the treatment stage of an investigational study are not eligible; please contact PI for further details on wash-out period and eligibility of such patients
Participating in any other investigational study for either drug or device which could influence collection of valid data under this study
Patients who have received an investigational agent or have used an investigational device within 4 weeks of the first dose of study drug
Currently enrolled in another interventional clinical study or used any investigational drug or device within the past 28 days preceding informed consent
Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)
Prior treatment with any investigational drug or device within 30 days prior to Randomization (within 2 weeks for investigational or approved immunotherapy) or currently participating in other investigational procedures;
Subject has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study.
Participating in another investigational drug or device study in which patient has not completed the follow-up phase for the primary endpoint at least 30 days prior to enrollment
Use of an investigational drug in the 3 months prior to screening and must agree to not participate in any drug or device study while enrolled in this study
Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
Has participated in a study with an unapproved investigational compound (monoclonal antibodies are excepted) or device within 28 days of the first dose of study drug
Patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administration
Patient has participated in a clinical study of an investigational drug or device within 3 months prior to screening CDU that may have an impact on clinical outcomes; and,
Treatment with any investigational drug, device or biologic agent within 30 days prior to administration of [18F]-ML-10.
Current enrollment in an investigational drug or device study, or participation in such a study within 30 days of first administration of the hormonal agent
Patient is participating in a clinical trial of another investigational drug or device
Planned participation in another study of an investigational agent or investigational device or use of a therapeutic device intended for therapy of glioma
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study.
Patient is participating in any other investigational drug or device study
Patient is participating in a clinical trial of another investigational drug or device
Receipt of an investigational drug or device within 30 days of enrollment.
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
Participation in another clinical study involving an investigational product within 1 month before study entry;
Participation in another clinical study with an investigational product during the last 1 month prior to initiation of therapy
Participation in another clinical study with an investigational product during the last 1 month
Participation in a study which involved medication within the last month
Participation in another clinical study in the month preceding this study
Patients who are participating in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of registration and throughout the duration of this trial are not eligible
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial
Participation in other therapeutic clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, such as monoclonal antibodies, within 30 days of the start of this trial and throughout the duration of this trial
Receipt of therapy on a clinical trial, including investigational and non-investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial; participation on non-therapeutic clinical studies is allowed, and patients who participated on a clinical trial for induction and/or transplant but who have completed the prescribed therapy course for that study and have been off therapy for at least 30 days are eligible
Participation in other clinical treatment trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21days of the start of this trial and throughout induction and consolidation 1 portions of this trial (while on MLN 9708); patients may enroll in transplant and post transplant studies after consolidation 1 treatment
Participation in clinical trials with other investigational agents not included in this trial, =< 30 days prior to registration
Participation in any other clinical trials with other investigational agents not included in this trial ? 21 days prior to registration
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 5 half lives of those investigational agents before the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, =< 30 days prior to registration and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials involving investigational agents within 21days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days prior to start of study treatment and throughout the duration of this trial
Participation in other clinical trials with investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial or throughout the duration of this trial
Participation in other clinical trials with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial. Non-interventional trials (that is, observational trials) are permitted at any time point.
Systemic anti-cancer therapy or participation in other clinical trials, including those with other investigational agents not included in this trial, ? 28 days of registration and throughout the duration of active treatment in this trial
Participation in clinical trials with other investigational agents not included in this trial throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and within 30 days of any dose of bortezomib
Participation in any other clinical trials with other investigational agents not included in this trial, =< 21 days prior to registration
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of the trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial and throughout the duration of this trial; within at least 5 half-lives of previous therapy for smoldering myeloma at start of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial (for all other standard therapies, no treatment within 14 days of the start of this trial)
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of bortezomib treatment on day +7; exceptions require approval of the study PI; and notifying Millennium Pharmaceuticals Incorporated (Inc.) within 72 hours
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial throughout the duration of this trial
Participation in other clinical trials with other investigational agents not included in this trial, within 21days of the start of this trial and throughout the duration of this trial
Participation in other clinical trials, including those with other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Treatment with other investigational agents, chemotherapy, or immunotherapy within 14 days of the start of this trial and throughout the duration of this trial
Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
Patient already included in this trial
Participation in other clinical trials utilizing other therapeutic investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
Are administered treatment with any other investigational agent or participation in another clinical study with anti-cancer therapeutic intent
Participation in another therapeutic clinical study or receiving any investigational agent within 28 days of enrollment or during this clinical study
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent
Participation in any other clinical trial within 4 weeks prior to randomization.
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to Day 1 of the study.
Participation in any clinical trial, within four weeks prior to registration on this trial, which involved an investigational drug or device
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug prior to enrollment
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
Subjects may not be receiving any other investigational agents or have participated in any other clinical trial involving another investigational agent for treatment of advanced solid tumors or lymphoma within 3 weeks prior to cycle 1, day 1 of the study.
Treatment with any investigational agent on a different clinical trial within 30 days of enrollment
Treatment with any investigational agent on a different clinical trial within 30 days of lymphodepleting chemotherapy
Treatment with any investigational agent or on an interventional clinical trial within 30 days prior to treatment on protocol
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to study entry;
Participation in a trial of an investigational agent within the prior 30 days
Treatment with any investigational agent or on an interventional clinical trial within 30 days prior to registration
Participation in an investigational therapeutic drug trial within 30 days of study entry
Participation in any other clinical trial involving another investigational agent for the treatment of AML within 2 weeks prior to day 1 of the study or at least 5 half-lives of the investigational agent, whichever is shorter
Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment
Participation in another clinical trial with drug intervention within 21 days prior to start of cycle 1 and during the study
Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Participation in another investigational trial within 90 days
Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks prior to study entry.
Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 4 weeks prior to study entry.
Participation in an investigational trial within 30 days of study entry
Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study
Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Concurrent participation in a clinical trial which involves another investigational agent
Participation in another clinical trial/investigation within 28 days prior to study drug
Treatment with any other test drug or participation in another clinical trial within 28 days of enrollment.
Participation in a clinical trial with an investigational therapy within 30 days prior to randomization
Participation in another clinical trial with any investigational drug within 30 days prior to study entry.
Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to randomization.
Concurrent participation in an investigational drug trial with therapeutic intent
Prior treatment in any other clinical trial involving another investigational agent within 4 weeks prior to Day -31 of the study; resolution of respective adverse event to Grade 1 or lower should have occurred
Systemic treatment on any investigational clinical trial within 28 days prior to registration.
Participation in a clinical trial involving an investigational drug within 30 days of study start
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Participation in an investigational therapeutic drug trial within 30 days of study entry
Participation in another investigational drug clinical trial
Current enrollment in another clinical trial involving treatment and/or is receiving an investigational agent for any reason
Patients who have participated in any therapeutic clinical study/received any investigational agent within the last 30 days are excluded from participation in this trial.
Participation in another investigational drug clinical trial.
Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during study
E 09. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
Concurrent participation or participation within the last 30 days prior to enrollment in any clinical trial with an investigational medicinal drug/chemotherapeutic or biologic or medical product.
Participation in another clinical trial or treatment with any investigational drug (excluding anticancer treatments) within 30 days of study start
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to day 1 of the study.
Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to the first dose of study treatment
Use of an investigational agent or participation in another clinical trial within 4 weeks prior to randomization
Participation in a trial of an investigational agent within the prior 30 days
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment; the following exceptions are allowed:\r\n* Unapproved/ experimental TKIs discontinued 14 days prior to cycle 1, day 1
Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to Day 1 of Cycle
Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to study entry
Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to the start of Cycle 1
Participation in another clinical trial in which they received active therapy within 4 weeks prior to the first dose of study drug.
Participation in another clinical trial or use of any investigational drug within 30 days prior to study entry
Concurrent treatment with an investigational agent or participation in another treatment clinical trial;
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrollment
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study drug
Investigational treatment or clinical trial within 4 weeks.
Current participation in a trial with another investigational agent, unless co-enrollment is approved by the principal investigators (PIs) of both studies
Participation in another clinical trial or use of another investigational agent within 30 days of study entry
Concurrent participation in a clinical trial which involves another investigational agent
Participation in another clinical trial involving an investigational product within 30 days prior to screening; or
The use of any investigational agent within 30 days preceding the first dose of the study vaccine or subsequent participation in another clinical trial at any time during the study period, in which the subject will be exposed to an investigational product
Receiving another investigational agent on a clinical trial that prohibits participation in other studies of investigational agents
Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment
Participant in a clinical trial involving an investigational drug within the past 30 days
Having received an investigational drug in an investigational drug trial within the last 30 days before randomization for this clinical trial. Participation in a clinical trial without receiving other investigational drugs (e.g. follow-up phase of a trial, observational study) is permitted. Part B, Exclusion criteria: All exclusion criteria as for Part A, except for inclusion criteria 1 and 12 which are replaced by:
Known intolerance to pritelivir or any of the excipients and 12. Having received an investigational drug in an investigational drug trial within the last 30 days before Day 1 for this clinical trial (except for subjects entering Part B who have previously received foscarnet treatment in Part A of this trial). Participation in a clinical trial without receiving other investigational drugs (e.g. follow-up phase of a trial, observational study) is permitted.
Patient included in another clinical trial involving an IMP within 30 days before the first investigational contrast agent injection.
Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolment
Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within 4 weeks prior to registration.
Participation in other studies involving investigational drug(s) within 28 days prior to study entry.
Participation in other clinical trials within at least 2 weeks of the first ORH-2014 dose;
Prior participation in a clinical study of viagenpumatucel-L
Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
Participation in any study involving administration of an investigational agent within 30 days of randomization into this study
Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.
Previous participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participation
Concurrent participation in other investigational drug trials.
Prior participation in an investigational study within 21 days of study day 1
Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
Current participation in another research or observational study.
Current participation in or previous participation in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment
Participation in other studies involving investigational drug(s) (phases 1-4) within 2 weeks before randomization in the current study
Participation to a study involving a medical or therapeutic intervention in the last 30 days
Prior participation in this study
Patients treated on any other therapeutic clinical protocols within 10 days prior to registration or during participation in the study
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
Participation in a clinical study involving receipt of an investigational drug during the last 30 days.
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
Subjects with leukemia are not eligible for study participation
Discontinued study participation in Verastem-sponsored IPI-145-07 study
Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation;
Any other investigational treatments within 4 weeks prior to and during study; includes participation in any medical device or other therapeutic intervention clinical trials
Current participation in another clinical study of an investigational agent, vaccine, or device. Concomitant participation in observational studies is acceptable after sponsor approval.
Participation in a prior investigational study within 30 days prior to enrollment
Participation in any previous study involving sipuleucel-T
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
agree to take a pregnancy test prior to starting study medication and throughout the study participation.
Females must abstain from breastfeeding during study participation and 3 months after IP discontinuation.
Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study
Current or recent treatment with another investigational drug within 30 days of first study treatment dosing or earlier participation in this study
Concurrent participation in any other investigational study
Participation in the active phase of other clinical trials of investigational agents in which last study treatment was administered within 2 weeks prior to randomization
Participation in another research study involving an investigational agent within 30 days prior to consent or projected study participation during the 28 days post study randomization.
Women must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from protocol treatment
Participation in a therapeutic research study or receipt of an investigational drug within 4 weeks of leukapheresis
Participation in any other clinical investigation within 4 weeks of receiving the first dose of study drug
Participation in any other research protocol involving administration of an investigational agent within 6 weeks prior to study entry
Participation in an investigational anti-cancer study within 3 weeks prior to day -7 (beginning of loading phase)
Participation in any other investigational drug study within 4 weeks of study enrollment
Participation in other studies involving investigational drug(s) within 4 weeks prior to study participation and/or during study participation.
Participation in concurrent investigational studies
Participation in an investigational therapeutic study within 3 weeks prior to first dose
Current participation in other clinical study
Participation in any clinical study or having taken any investigational therapy within 28 days.
participation in other investigational studies, unless approved in writing by the study sponsor.
current participation in other clinical study
Participation in other studies involving investigational drug(s) (Phases 1-4) within 4 weeks of registering for the current study and/or during study participation.
Participation in other studies involving investigational drug(s) (Phases 1-4) before the current study begins and/or during study participation.
Participation in clinical drug trials within 4 weeks
Participation in a therapeutic research study or receipt of an investigational drug within 30 days of T-cell infusion
Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 2 weeks prior to treatment in this study
Female patients may not be breastfeeding at screening and must not breastfeed during study participation through 45 days after the last dose of study drug.
Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study
Previous participation in a clinical study of Kevetrin
Participation in another clinical study with an investigational drug within 30 days of Screening.
Participated in any previous study of aprepitant or fosaprepitant, or taken an investigational drug within 4 weeks prior to study participation
Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment
Current participation in a treatment study or past participation in a study of an investigational agent within 4 weeks before the first dose of study treatment
Females must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation
Participation in an investigational therapeutic study within 14 days of initiation of study drug treatment
Likely to continue to need treatment of OIC for the duration of participation in the study.
Participation in a study with an investigational drug from 4 weeks prior to study start until study end
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
Participation in any other clinical study within the last 4 weeks prior to the start of the study
Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of the study drug.
Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.
(Physician participation) seeing the patient in consultation on the day of the study
Participation in a therapeutic research study within 30 days of baseline
Concomitant participation in any other investigational treatment study; simultaneous participation in non-therapeutic or observational studies will not be an exclusion criterion
Declined participation in the study
Approval of Oncology provider for participation in this study
Participation in any other investigational treatment within the 6 weeks prior to enrollment or concurrent with this study.
Prior participation, i.e., receipt of study medication, in this study;
Participation in another clinical study within 28 days of the day chemotherapy is initiated, in which the study drug or device may influence hematopoiesis. Co-enrollment in another study is allowed in cases where the investigational therapy under study is a version of an acceptable chemotherapy regimen for this study per the inclusion criteria.
Previous participation in this study
Participation in another research project that might interfere with completion of this study
Medical clearance from treating clinician for study participation
Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study
Participation in other research protocols does not exclude a patient from participation in this study
Participation in any other study in last 30 days
Participation in other clinical study within the last 30 days
Patient has completed participation in another clinical study involving administration of an investigational agent in the preceding 4 weeks. However, participation in clinical studies involving other investigational PET or SPECT tracers will not be excluded if in the opinion of the Investigator:
Participation in more than 3 research studies in the past 6 months. Participation in a smoking study in the past 6 months. Participation in a study which involved medication within the last month
Participated in a therapeutic clinical study within 3 weeks before study drug treatment, or current participation in other therapeutic investigational procedures.
Participated in a therapeutic clinical study within 3 weeks before study drug treatment, or current participation in other therapeutic investigational procedures.
Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment
Participated in a therapeutic clinical study within 3 weeks (2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents) before study drug treatment, or current participation in other therapeutic investigational procedures.
Systemic treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or treatment with small-molecule targeted agents within 2 weeks, or 5 half-lives before study drug treatment, whichever is longer.
Participation in a therapeutic clinical study within 3 weeks before study drug treatment (for small-molecule targeted agents, this non-participation period is 2 weeks or 5 half-lives, whichever is longer), or current participation in other investigational procedures.
Have participated in another therapeutic clinical trial with an investigational drug within 1 month
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients may not be receiving any other investigational agents; if patients are currently part of or have participated in any clinical investigation with an investigational drug, the last administration of the investigational study should be at least 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing (except ALK inhibitors)
Patients who are currently part of or have participated in any clinical investigation with an investigational therapeutic drug within 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 30 days prior to dosing.
Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients, who in the opinion of the investigator, are unlikely to comply with follow-up visits or other study requirements; patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Subject currently enrolled in any other clinical investigation or who has participated in any clinical investigation in the 30 days prior to starting this study.
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Patients who have participated in a clinical trial of an investigational drug within 12 months prior to enrollment
Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment.
The patient participated in another clinical investigation within 30 days of enrollment or is receiving another investigational agent.
Participation in another clinical study with an investigational product during the 21 days prior to first dose of olaparib and temozolomide
Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion)
Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e. D1 of cycle 1)
Participation in another clinical study with an investigational product during the last 30 days
Participation in another clinical study with an investigational product during the last 4 weeks.
Participation in another clinical study with an investigational product during the 4 weeks prior to therapy initiation
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 6 months
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product administered during the last 28 days.
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 4 weeks (prior use of bevacizumab in the upfront setting is allowed)
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product for cancer during the last 12 months
Participation in another clinical study with an investigational product during the last 6 months (mo)
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 3 months
Participation in another clinical study with an investigational product (IP) during the last 3 weeks before the first day of study treatment
Participation in another clinical study with an investigational product during the last 3 weeks
Participation in another clinical study with an investigational product during the last 4 weeks or 5 half-lives prior to starting on treatment.
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the last 21 days
Participation in another clinical study with receipt of an investigational product during the last 4 weeks
Concurrent enrollment in another therapeutic clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion)
Participation in another clinical study with an investigational product during the last 14 days
Participation in another clinical study with receipt of an investigational product during the last 4 weeks
Participation in another clinical study with an investigational product during the previous 4 weeks
Participation in another clinical study with an investigational product during the last 4 weeks
Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment (i.e., D1 of Cycle 1)
Participation in another clinical study with an investigational product during the last 14 days
Participation in another clinical study with an investigational product during the last 14 days
Participation in another clinical study with an investigational product during the last 21 days
Known or suspected allergy to the investigational agent or any agent given in association with this trial.
Known or suspected allergy to the investigational agent or any agent given in association with this trial
Known or suspected allergy to lenvatinib or any agent given in the course of this trial
Known or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trial
History of ? grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.
Known or suspected allergy to any agent given in the course of this trial
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known or suspected allergy to the investigational agent or any agent given in association with this trial
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known or suspected allergy to gemcitabine or MLN8237, or any agent given in the course of this trial
Known or suspected allergy to irinotecan or MLN8237, or any agent given in the course of this trial
Known or suspected allergy to sorafenib (BAY 43-9006) or any agent given in association with this trial
Known or suspected allergy to the investigational agent or any agent given in association with this trial.
Known or suspected allergy to sorafenib
Known or suspected allergy to sorafenib or any agent given in the course of this trial
Known or suspected allergy to any agent given in the course of this trial
